At 68 weeks more participants in the semaglutide group reached bodyweight reductions of at least
Semaglutide: 85% | Placebo: 26%
Odds ratio (OR) 12.6 (95% CI, 8.5 to 18.7) | P<0.0001
Semaglutide: 69% | Placebo: 12%
OR 14.7 (95% CI, 9.6 to 22.6)
Semaglutide: 54% | Placebo: 6%
OR 17.9 (95% CI, 10.4 to 30.7)
Semaglutide: 34% | Placebo: 3%
OR 18.5 (95% CI, 8.8 to 38.9)
Individuals in the semaglutide group had a 57.3% reduction in high-sensitivity C-reactive protein (marker for systemic inflammation associated with future cardiovascular risk)
Adverse events were more frequent with semaglutide
Semaglutide: 92% | Placebo: 86%
Gastrointestinal adverse events (mostly mild to moderate) were reported in more participants in the semaglutide group
Semaglutide: 80% | Placebo: 46%
In adults without type 2 diabetes, the use of oral semaglutide led to a greater reduction in bodyweight than placebo
The authors state
In conclusion, oral semaglutide 50 mg taken once per day, the first oral GLP-1 receptor agonist to be investigated for the treatment of obesity in adults with overweight or obesity, was shown to induce substantial, clinically meaningful bodyweight reductions as an adjunct to diet and physical activity
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan